Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
AxoGen (AXGN) Receives a Hold from Canaccord Genuity - Markets
04:44pm, Tuesday, 13'th Oct 2020
Canaccord Genuity analyst Kyle Rose maintained a Hold rating on AxoGen (AXGN – Research Report) on October 11 and set
AxoGen Struggling Through A Protracted Restructuring (NASDAQ:AXGN)
06:34am, Friday, 02'nd Oct 2020
COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
08:01pm, Wednesday, 30'th Sep 2020
ALACHUA, Fla., Sep 30, 2020 (GLOBE NEWSWIRE via COMTEX) --
Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors...
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
08:01pm, Wednesday, 30'th Sep 2020
ALACHUA, Fla., Sep 30, 2020 (GLOBE NEWSWIRE via COMTEX) -- Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors...
Jacobs Levy Equity Management Inc. Purchases New Stake in AxoGen, Inc (NASDAQ:AXGN)
07:24am, Monday, 21'st Sep 2020
Jacobs Levy Equity Management Inc. acquired a new position in AxoGen, Inc (NASDAQ:AXGN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Th
Is AxoGen's (NASDAQ:AXGN) 219% Share Price Increase Well Justified?
01:48pm, Friday, 07'th Aug 2020
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
11:45pm, Wednesday, 05'th Aug 2020
AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Axogen, Inc. Reports Second Quarter 2020 Financial Results
08:01pm, Wednesday, 05'th Aug 2020
ALACHUA, Fla., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fi
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
12:00am, Wednesday, 05'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
04:33pm, Wednesday, 29'th Jul 2020
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
11:00am, Wednesday, 29'th Jul 2020
ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves
BioNTech COVID-19 Progress, And Other News: The Good, Bad And Ugly Of Biopharma
10:43am, Thursday, 23'rd Jul 2020
BioNTech reports positive COVID-19 vaccine data with Pfizer, receives $2 billion order from US Govt. AxoGen completes enrollment in pivotal nerve graft study.
Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
11:00am, Wednesday, 22'nd Jul 2020
RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve GraftALACHUA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global l
Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020
11:00am, Wednesday, 15'th Jul 2020
ALACHUA, Fla., July 15, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.
